interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Palopegteriparatide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Palopegteriparatide, and who makes it?

Palopegteriparatide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Palopegteriparatide1 dosage-form group in the Orange Book
0generic makers listed
  1. Palopegteriparatide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Solution, Subcutaneous

Brand listed, no generic listed as marketed

Brand listed as marketed: Yorvipath. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 8906847 listed to expire 30 April 2031Patent 12453778 listed to expire 28 September 2037Patent 12295989 listed to expire 28 September 2037Patent 11857603 listed to expire 28 September 2037Patent 11590207 listed to expire 28 September 2037Patent 11890326 listed to expire 28 September 2037Patent 11918628 listed to expire 28 September 2037Patent 11759504 listed to expire 28 September 2037Patent 12403182 listed to expire 12 November 2042Exclusivity NCE to 9 August 2029Exclusivity ODE-492 to 9 August 2031
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 9 August 2029Exclusivity NCE Yorvipath
  • 9 August 2031Exclusivity ODE-492 Yorvipath
  • 30 April 2031Patent 8906847 drug substance
  • 28 September 2037Patent 12453778
  • 28 September 2037Patent 12295989
  • 28 September 2037Patent 11857603
  • 28 September 2037Patent 11590207
  • 28 September 2037Patent 11890326 drug substance
  • 28 September 2037Patent 11918628 drug substance
  • 28 September 2037Patent 11759504 drug product

1 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.